

FOR IMMEDIATE RELEASE

For More Information Contact:

Michael Schmainda
Imaging Biometrics, LLC
(262) 439-8252 • mike@imagingbiometrics.com



IMAGING BIOMETRICS JOINS NATIONAL IMAGING NETWORK

For Immediate Release

July 16, 2014

Elm Grove, WI – Imaging Biometrics, LLC (IB), a biotechnology company specializing in the development of software solutions for advanced visualization and analytics, announced its participation in a national network of imaging investigators focused on translating novel imaging technologies from leading institutions across the country. The overall goal is to accelerate the translation of novel imaging systems and/or methods that are designed to solve a target cancer problem.

This work is being done as part of a \$2.2 million, five-year grant from the National Institutes of Health (NIH), of which IB is a sub awardee. Under this grant, research and laboratory resources will combine with industrial expertise to develop and validate standard and novel imaging biomarkers to monitor treatment response in patients with brain tumors. Through this collaborative network, an anticipated outcome will be the enhanced probability of commercial production of the proposed imaging system or method.

“Standard methods of measuring tumor enhancement are no longer sufficient as advances in treatment therapies have made the tracking of tumor progression very challenging. This project addresses an urgent need for better ways to monitor targeted therapies,” said Timothy Dondlinger, Chief Operating Officer.

The federal funds of this U01 grant mechanism will be used to research, develop and translate into practice both standard and novel perfusion-weighted MRI (PWI) and diffusion-weighted MRI (DWI) biomarkers for both clinical trials and standard medical care. While both PWI and DWI have demonstrated promise for treatment monitoring, preliminary studies suggest the combined image maps may present the most complete assessment of treatment response. When included with patented technology from IB and exclusively-licensed technology from other institutions, the result of this NIH grant will be an integrated image analysis platform for use in large-scale multi-center clinical trials. Moreover, this effort may result in a robust and ready to use advanced imaging platform that may lead to greater clinical trial efficacy, more rapid drug discovery and commercialization, and improved care for patients.

Mr. Dondlinger added, “This addresses a critical need for patients with brain tumors. We anticipate rapid translation and widespread deployment of developed technologies via a low-cost, yet sophisticated, solution that will help clinicians help patients.”

FOR IMMEDIATE RELEASE

For More Information Contact:

Michael Schmainda
Imaging Biometrics, LLC
(262) 439-8252 • mike@imagingbiometrics.com



About Imaging Biometrics™ LLC

Imaging Biometrics develops and provides visualization and analytical solutions that enable clinicians to diagnose and treat diseases with greater confidence. Through close collaboration with top researchers and clinicians, sophisticated advancements are translated into platform-independent software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB's advanced visualization software seamlessly integrates into routine workflows. For more information about Imaging Biometrics, visit the company's website at www.imagingbiometrics.com.